UBS Oncology Impact Fund L.P. - 10%+ Owner at Cullinan Therapeutics, Inc.

Issuer-level insider activity

Role
10%+ Owner
Issuer ticker
CGEM on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Company
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by UBS Oncology Impact Fund L.P. since 02 Sep 2025

Reported holdings for UBS Oncology Impact Fund L.P. in Cullinan Therapeutics, Inc.

Form 4 holding 10%+ Owner

Cullinan Oncology, Inc.

Security class
Common Stock
Shares / value
7,648,268
Estimated value
$95,297,419
Report date
16 Sep 2021
Price
$12.46
Ownership
Direct

Transaction history for UBS Oncology Impact Fund L.P. in Cullinan Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .